Current and Emerging Therapy on Lupus Nephritis
Abstract
Keywords
References
Patel M, Clarke AM, Bruce IN, Symmons DP. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheumatol. 2006;54(9):2963-9.
Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174–94.
Yap D, Tang C, Ma M, Lam M, Chan T. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27(8):3248-54.
Bomback SA, Appel GB. Updates on the treatment of lupus nephritis. JASN. 2010;21(12):2028-35.
Pramono LA, Karim B, Rajabto W, Siregar P, Sukmana N, Setyohadi B. Mycophenolate mofetil versuscyclosphophamide for therapy of lupus nephritis: an evidence-based case report from systematic reviews and meta-analyses. Med J Indones. 2012;21:44-51.
Lanz O, Waheed AA, Baig A, Pop A, Contreras G. Lupus nephritis: maintenance therapy for lupus nephritis-do we now have a plan?. CJASN. 2013;8(1):162-71.
Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH. Therapy of lupus nephritis. controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614-9.
Appel GB. New and future therapies for lupus nephritis. CCJM. 2012;79(2):134-40.
Ginzler EM, Dooley MA, Arranow C, et al. Mycophenolate mofetil or intravenous cyclosphophamide for lupus nephritis. N Engl J Med. 2005;353:2219-28.
Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2004;350:971-80.
Appel GB, Contreras G, Doole MA, et al. Mycophenolate mofetil versus cyclosphophamide for induction of lupus nephritis. JASN. 2009;20(5):1103-12.
Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-60.
Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis. Ann Intern Med. 2015;162:18-26.
Bao H, Liu ZH, Zie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-10.
Ikeuchi H, Hiromura K, Takahashi S, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol. 2014;24(4):618-25.
Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials. Am J Kidney Dis. 2017;70(3):324-36.
Kidney Disease Improving Global Outcomes (KDIGO), KDIGO Clinical Practice Guideline for Glomerulonephritis. 2012. Available from: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf [Accessed 22nd November 2017].
Irastorza GR, Espinosa G, Frutos MA, et al. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine and the Spanish Society of Nephrology (S.E.N.). Nefrolgia. 2012;32(1):1-35.
Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-909.
Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2016; doi:10.2215/CJN.05780616.
Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. Arthritis Rheumatism. 2012;64(4):1215-26.
Eknoyan G, Lameire N, Eckardt K, et al. KDIGO clinical practice for glomerulonephritis. Kidney Intl Suppl. 2012;2(2):221-32.
Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and and European Renal Association—European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-82.
Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886-95.
Houssiau FA, Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis. 2010;69:2083-9.
Ruiz IG, Espinosa G, Frutos MA. Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012;32(1):1-35.
Arends S, Grootscholten C, Derksen RH, Berger SP, de Sevaux RG. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012;71(6):966-73.
Tellingen AV, Voskuyl AE, Vervloet MG, et al. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Netherlands J Med. 2012;70(4):199-206.
Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res and Ther. 2015;17:110.
Haladyj E, Cervera R. Do we still renal biopsy in lupus nephritis? Reumatologia. 2016;54(2):61-6.
Ronbloom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol. 2011;23:113-21.
Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammaco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008;58:251-62.
Rovin BH, Furie R, Latinis K, et al. LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with Rituximab study. Arthritis Rheum. 2012;64:1215-26.
Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis guidelines and perspective from Asia. Nephrol. 2014; doi:10.1111.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Lupus nephritis collaborative study group: long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol. 1996;7:299-305.
Dooley MA, Houssiau F, Aranow C, et al. BLISS-52 and -76 Study Group: Effect of belimumab treatment on renal oucomes in patients with SLE. Lupus. 2013;22:63-72.
Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Eng J Med. 2014;370:1101-10.
Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393-02.
Rovin BH, Dooley MA, Radhakrishnan J, et al. The impact of tabalumab on the kidney in systemic lupus erythematosus: results from phase 3 clinical trials. Lupus. doi: 10.11177/0961203316650734.
Pollard RP, Abdulahad WH, Vissink A, et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjorgen’s syndrome: data from a placebo-controlled clinical trial. Ann Rheum Dis. 2013;72:146-8.
Cheng Q, Mumtaz IM, Khodadadi L, et al. Autoantibodies from long-lived memory plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis. 2013;72:2011-7.
Espeli M, Boekrs S, Giannco G, et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol. 2011;22:296-305.
Hiepe F, Domer T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7:170-8.
Furie R, Merrill JT, Werth VT, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody in moderate to severe systemic lupus erythematosus. Am Coll Rheumatol. 2015.
Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148:313-21.
Glikeson GS. Complement targeted therapies in lupus. Current Treat Options Rheum. 2015;1:10-18.
Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25:225-31.
Refbacks
- There are currently no refbacks.